MapLight Therapeutics, Inc. (MPLT)
NASDAQ:MPLT
MPLT Stock Chart & Stats
$17.49
--
Market closed
$17.49
--
Day’s Range― - ―
52-Week Range$12.24 - $21.55
Previous CloseN/A
VolumeN/A
Average Volume (3M)401.63K
Market Cap
$872.52M
Enterprise Value-$43.50M
Total Cash (Recent Filing)$227.17M
Total Debt (Recent Filing)$6.01M
Price to Earnings (P/E)―
Beta0.28
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding45,373,030
10 Day Avg. Volume205,334
30 Day Avg. Volume401,626
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)1.69
Price to Sales (P/S)0.00
P/FCF Ratio-5.58
Enterprise Value/Market Cap-0.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit99.31
Enterprise Value/Ebitda0.41
Forecast
1Y Price Target
$35.00Price Target Upside100.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-3.67
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash RunwayA funded runway into 2027 provides meaningful near-term optionality to complete multiple Phase 2 programs without immediate financing. That reduces near-term dilution risk, supports milestone-driven development, and gives management time to de-risk assets before seeking large-scale commercialization funding.
Low Leverage / Strong Balance SheetVery low leverage and sizable equity position supply strategic flexibility: low interest burden, capacity to fund R&D via equity or partnerships, and resilience in capital markets stress. This underpins the company's ability to execute multi-year clinical programs without material interest expense pressure.
Pipeline Depth & Regulatory ProgressA diversified CNS pipeline plus Fast Track designation is a structural advantage: multiple programs lower single-binary risk and Fast Track can accelerate regulatory interactions. Together these strengthen long-term commercial prospects if Phase 2 data validate efficacy and safety.
Bears Say
Accelerating Cash BurnMaterial negative operating cash flow that nearly doubled year-over-year elevates funding risk: sustained high burn shortens the effective runway and increases probability of future capital raises, which could be dilutive and divert management focus from R&D execution to financing.
No Revenue & Widening LossesAs a pre-revenue biotech, the company depends entirely on successful clinical outcomes for value creation. The doubling of net losses reflects rising expense intensity and weak operating leverage, making long-term viability contingent on clinical success or continued external funding.
Dependence On External FundingEven with current cash, negative free cash flow and volatile FCF trends mean the company will likely need additional capital to reach commercialization. Reliance on markets or partners creates execution and dilution risk, and could constrain strategic choices if financing terms tighten.
MapLight Therapeutics, Inc. News
MPLT FAQ
What was MapLight Therapeutics, Inc.’s price range in the past 12 months?
MapLight Therapeutics, Inc. lowest stock price was $12.24 and its highest was $21.55 in the past 12 months.
What is MapLight Therapeutics, Inc.’s market cap?
MapLight Therapeutics, Inc.’s market cap is $872.52M.
When is MapLight Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were MapLight Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is MapLight Therapeutics, Inc. overvalued?
According to Wall Street analysts MapLight Therapeutics, Inc.’s price is currently Undervalued.
Does MapLight Therapeutics, Inc. pay dividends?
MapLight Therapeutics, Inc. does not currently pay dividends.
What is MapLight Therapeutics, Inc.’s EPS estimate?
MapLight Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MapLight Therapeutics, Inc. have?
MapLight Therapeutics, Inc. has 45,373,030 shares outstanding.
What happened to MapLight Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of MapLight Therapeutics, Inc.?
Currently, no hedge funds are holding shares in MPLT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MapLight Therapeutics, Inc. Stock Smart Score
Company Description
MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. MapLight Therapeutics, Inc. was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California. MapLight Therapeutics, Inc operates as a subsidiary of Catalyst4, Inc.
MPLT Stock 12 Month Forecast
Average Price Target
$35.00
▲(100.11% Upside)
Scinai Immunotherapeutics
―
Sensei Biotherapeutics
―
GRI Bio
―
Dermata Therapeutics
―
Azitra Inc
―